FABP4 and cancer: However, the supposed basic mechanism of an adipocyte-driven tumour progression in SARIFA-positive cancers may provide the basis for pharmacological intervention targeting the tumour cell metabolism with existing drugs such as Metformin, FABP4-inhibitors [16, 17] or CD36 [18, 19].